Project Grant R43AA032950
Award Date 9/1/26
Completion Date 2/28/27
Dollars Obligated $314K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Hanover, NH 03755, USA
Similar Awards
- The National Institute on Alcohol Abuse and Alcoholism awarded Here & Now Systems LLC $306,746 on July 1, 2026, to develop an enhanced version of the STEP AWAY Alcohol Manager (SAAM), a mobile health intervention for alcohol use disorder treatment, under the Alcohol Research Programs (CFDA 93.273). SAAM is a mobile application that delivers personalized alcohol intervention through integration of artificial intelligence and biometric monitoring. The Phase I project incorporates multi-agent...
- The National Institute on Alcohol Abuse and Alcoholism awarded Washington State University $498,203 under the Alcohol Research Programs (CFDA 93.273) on August 1, 2026, to develop a just-in-time adaptive music-listening mobile health intervention for stress reduction among individuals in early recovery from alcohol use disorder. The research aims to create the first music-listening intervention leveraging passive sensing and machine learning to automatically predict and respond to moments of...
- The National Institute on Alcohol Abuse and Alcoholism awarded Witii Pharmaceuticals, Inc. $306,149 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to develop a novel once-daily extended-release formulation of acamprosate calcium for alcohol use disorder. The recipient will optimize an extended-release tablet formulation designed to maintain therapeutic drug levels for 18 to 24 hours, replacing the current regimen of twice-daily 333 mg delayed-release tablets taken...
- The National Institute on Alcohol Abuse and Alcoholism awarded Leaflabs, LLC $499,971 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to develop a novel organoid brain-chip platform for accelerating central nervous system drug discovery. The recipient will design and build a fully automated, purpose-built organoid brain-on-a-chip platform to overcome barriers limiting adoption of brain organoid technology in drug development. The platform will internally perfuse...
- The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $576,197 on September 16, 2025, under the Alcohol Research Programs (CFDA 93.273) to develop and test a digital pill system paired with smartphone-delivered cognitive behavioral therapy to measure and support acamprosate adherence in individuals with alcohol use disorder and alcohol-associated liver disease. Yale will develop a user-centered adherence intervention called ACAMPROSYNC that combines a digital pill system...
- The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $182,183 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to develop artificial intelligence agents that generate personalized, multimedia cognitive behavioral therapy content for alcohol use disorder treatment, targeting English speakers and Spanish speakers. The project will create AI-generated CBT content delivered via smartphone to address high-risk drinking periods, such as weekends. The...
- The National Institute on Alcohol Abuse and Alcoholism awarded the University of Rhode Island $1,403,716 on September 20, 2025, under the Alcohol Research Programs (CFDA 93.273) to examine transactional relationships between sensor-derived alcohol use data and acute suicide risk during community re-entry following residential alcohol use disorder treatment. The research uses ecological momentary assessment and transdermal alcohol sensor technology (BACtrack Skyn) to assess time-varying,...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded Massachusetts General Hospital a $735,930 Project Grant (R34) on September 23, 2025, under the Alcohol Research Programs (CFDA 93.273) to develop, validate, and conduct an open trial of a large language model (LLM)-based conversational agent for delivering brief alcohol interventions to emerging adults ages 18-29. The project, which runs through August 31, 2028, addresses the critical public health need to expand screening...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Johns Hopkins University $616,371 under the Alcohol Research Programs (CFDA 93.273) on June 10, 2026, to conduct a double-blind randomized controlled trial testing daridorexant, a dual orexin receptor antagonist, for reducing alcohol craving and use and improving total sleep time in patients with alcohol use disorder and co-occurring sleep disturbance. Participants recruited from a residential treatment facility will be...
- The National Institute on Alcohol Abuse and Alcoholism awarded Behavior Change Hub LLC $303,008 on July 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to develop a didactic and interactive simulation training product targeting provider knowledge and skill in alcohol misuse and alcohol use disorder treatment. The training suite, called the Behavioral Health Counseling Competencies AUD Training Suite, integrates NIAAA's Rethinking Drinking dissemination resource with four core...